New options for outpatient chemotherapy - The role of oral fluoropyrimidines

Cancer Treatment Reviews

Volumn 27, Issue 4, 2001, Pages 211-220

  Cunningham, D ^a   Coleman, R ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Capecitabine; Colorectal cancer; Eniluracil; Oral fluoropyrimidines; UFT

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5 ETHYNYLURACIL; ANTHRACYCLINE; CAMPTOTHECIN; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; SATRAPLATIN; TAXOID; TEGAFUR; UFT; URACIL;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOTENSION; LEUKOPENIA; METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; OUTPATIENT CARE; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR;

EID: 0034842983     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2001.0229     Document Type: Article

References (67)

1. 5-fluoropyrimidines
2. Treatment of breast cancer
3. 5-fluorouracil in colorectal cancer: Rationale and clinical results of frequently used schedules
4. Development of treatment for advanced colorectal cancer: Infusional 5-FU and the role of new agents
5. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A mid-Atlantic Oncology program study
6. Colorectal cancer: The challenge
7. Antimetabolites
8. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
9. 24h) with or without folinic acid (FA) vs. bolus 5-FU/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): A randomized phase III study of the EORTC GITCCG and the AIO
10. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
11. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma
12. Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration, and cost comparison
13. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer
14. Current management of advanced breast cancer
15. Treatment decisions in palliative cancer care: Patients' preferences for involvement and doctors' knowledge about it
16. Assessing patients' needs and preferences in the management of advanced colorectal cancer
17. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy
18. Patient preferences for chemotherapy schedules used in the treatment of advanced colorectal cancer - A pilot study
19. Patient preferences for oral versus intravenous palliative chemotherapy
20. A randomized crossover trial comparing oral UFT (uracil/tegafur) + leucovorin (LV) and intravenous fluorouracil (FU) + LV for patient preference and pharmacokinetics in advanced colorectal cancer
21. A study of quality of life in cancer patients receiving palliative chemotherapy
22. Quality of life issues in the treatment of metastatic breast cancer
23. Oral chemotherapy: Rationale and future directions
24. Thymidylate synthase inhibitors in cancer therapy: Direct and indirect inhibitors
25. New drugs in the treatment of colorectal carcinoma
26. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer
27. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil
28. Phase I trial of uracil-tegafur (UFT) using 5 and 28 day administration schedules: Demonstration of schedule dependent toxicities
29. The oral fluorouracil prodrugs
30. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors
31. Phase I and pharmacologic study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
32. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors
33. A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer
34. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer
35. Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: A phase II study
36. Promising activity with eniluracil (776C85) and oral 5-fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer: A phase II study
37. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
38. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast cancer patients
39. A randomized phase II study of Xeloda™ (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy
40. Advanced colorectal carcinoma: Redefining the role of oral ftorafur
41. Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma
42. Tegafur-uracil (UFT) plus folinic acid in advanced rectal cancer
43. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer
44. Capecitabine as first-line treatment for colorectal cancer (CRC): Integrated results of 1207 patients (pts) from 2 randomized, phase III studies
45. Post-operative chemoendocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer
46. Tegafur and uracil (UFT®) as post-operative adjuvant chemotherapy for breast cancer - Meta-analysis of five clinical studies
47. Experience with UFT in Japan
48. A new 5-fluorouracil prodrug, S-1, orally bioavailable with high therapeutic index in model system active in phase II trials
49. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma
50. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissues
51. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
52. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients
53. Capecitabine (Xeloda™), an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
54. Oral capecitabine with metastatic colorectal cancer: Results of a large phase II study
55. Comparison of oral capecitabine versus intravenous fluorouracil plus levcovonin as first-line treatment in 605 patients with metastatic colectoral cancer: Results of a randomized phase III study
56. First-line capecitabine treatment for metastatic breast cancer (MBC): Updated data from a randomised phase II trial
57. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda® (capecitabine)
58. Results of a large phase III trial of Xeloda®/Taxotere® combination therapy vs Taxotere® monotherapy in metastatic breast cancer (MBC) patients
59. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies
60. A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients
61. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
62. Efficacy and safety profile of capecitabine (Xeloda®) in combination with paclitaxel (P) in patients with locally advanced or metastatic breast cancer: Preliminary results of a phase II study
63. Safety profile and preliminary efficacy of capecitabine (Xeloda®) in combination with oxaliplatin in patients with advanced or metastatic solid tumours: Results from a phase I study
64. Phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer
65. Phase I study of capecitabine combined with standard radiotherapy in patients with rectal cancer
66. Phase II clinical trial with the combination of oxaliplatin-UFT-1, -leucovorin (OXA-UFT-1, LV) for the first line treatment of advanced colorectal cancer (ACC)
67. A phase I/II study of oral uracil/tegafur (UFT®) leucovorin and irinotecan in patients with advanced colorectal cancer